69 results about "Protein Fragment" patented technology

Hyaluronic acid and silk protein fragments based tissue fillers and methods of using the same are provided herein.

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

The application provides a marker for diagnosing systemic inflammation and application, the marker comprising ADGRE3 mRNA or ADGRE3 protein, or ADGRE3 mRNA fragment, ADGRE3 protein fragment, and the marker content in samples of systemic inflammation patients and healthy people has significant difference, and the marker diagnosis has high sensitivity and specificity in clinical verification, therefore, by detecting the ADGRE3 mRNA transcription level or the ADGRE3 protein expression level in the individual sample, systemic inflammation can be accurately diagnosed.Compared with existing inflammation markers, ADGRE3 mRNA and ADGRE3 protein have higher sensitivity and specificity in diagnosing systemic inflammation.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The invention discloses a macromolecular protein cutting method and system based on multi-source protein feature scoring, and a storage medium, and belongs to the field of computational biology and intelligent drug research and development. In order to solve the technical problem that macromolecular protein is difficult to directly input into an existing calculation model, an amino acid position cutting comprehensive score is obtained by obtaining multi-source feature data such as a protein disorder region and structural domain annotation, candidate cutting sites are screened and a final cutting scheme is determined in combination with double constraints of a structural domain hard boundary and fragment length, and the method is suitable for large-scale industrial production. And generating a protein fragment adaptive to downstream calculation. According to the method, the integrity of the protein structural domain is guaranteed, the cut fragment can be directly used as model input such as AlphaFold, the accuracy and stability of structural prediction and molecular docking are improved, the method is suitable for scenes such as virtual screening and computer-aided drug design, and the problem that an existing cutting method is lack of systematic consideration is solved.

The present disclosure relates to a novel platform for the design of multi-specific antibodies, incorporating innovative splits of antibodies, cytokines, or other proteins at various positions within a single antibody framework. This design aims to reduce toxicity and enhance therapeutic efficacy, particularly in applications such as immunotherapy and antibody-drug conjugates (ADCs). Multi-specific antibodies—including monospecific, bispecific, and multi-specific forms—comprise one or more antigen-binding domains that engage one or more epitopes of the same or different antigens. This disclosure encompasses methods for producing antibodies with one, two, or multi antigen-binding domains, which may consist of immunoglobulin heavy chain variable domains alone or in combination with other functional domains.

The invention relates to an infectious bronchitis subunit vaccine based on a nano-skeleton technology. Specifically, the invention provides a fusion protein which sequentially comprises an infectious bronchitis virus S protein fragment or a mutant thereof, a connecting peptide and helicobacter pylori ferritin from an N terminal to a C terminal, wherein the infectious bronchitis virus S protein fragment is S1 protein, and the amino acid sequence of the S protein fragment is as shown in SEQ ID NO. 2; the mutant of the chicken infectious bronchitis virus S protein fragment is S1-2 protein or S1-3 protein, the amino acid sequence of the S1-2 protein is shown as SEQ ID NO.4, and the amino acid sequence of the S1-3 protein is shown as SEQ ID NO.5. The invention further discloses a preparation method of the chicken infectious bronchitis virus S protein fragment.

The invention belongs to the technical field of biology, and particularly relates to a Prussian blue nano test strip for detecting an African horse pestivirus antibody as well as a preparation method and application of the Prussian blue nano test strip. A sample pad, a combination pad, a chromatography detection membrane and a water absorption pad are sequentially fixed on the supporting bottom plate; the chromatography detection membrane is provided with a detection line and a quality control line, the detection line is coated with staphylococcus A protein, and the quality control line is coated with a monoclonal antibody of African horse pestivirus VP7 recombinant protein; and the combination pad is coated with an African horse pestivirus VP7 delta N1-129 recombinant protein fragment coupled with Prussian blue nanoparticles. According to the invention, Prussian blue nano is used as a coupling tracer, and the specific reaction of an antigen and an antibody is fully utilized to detect the African horse pestivirus antibody. After the conjugate is combined with a corresponding antibody, a result can be clearly observed, and the conjugate is good in stability, high in sensitivity and strong in specificity, has a clinical application function and huge development potential, and is an extremely ideal antibody test strip detection material.

The invention discloses a protease cleavable liposome and application thereof in treating colon cancer. The preparation method of the protease cleavable liposome comprises the following steps: synthesizing functional peptide from cancer homing peptide, protease cleavable protein fragments and lysine; the preparation method comprises the following steps: reacting a functional peptide with difunctional polyethylene glycol COOH-PEG2000-Mal, and covalently linking the obtained product with DSPE-NHS to obtain a protease cleavable material; and coupling the aPDL1 antibody to a protease cleavable material to obtain the protease cleavable liposome. The protease cleavable liposome can activate cytokines to kill tumor cells, so that effective endocytosis by colon cancer cells is realized, and an immune checkpoint blocking effect is achieved. Therefore, the protease cleavable liposome not only can be used as an effective delivery carrier for immune checkpoint blocking treatment, but also can be used as a universal platform for colon cancer immunochemistry combined treatment. The method has an important application value.

The invention relates to the technical field of genetic engineering, in particular to identification of a new insertion site of a self-assembled protein cage nanoparticle antigen epitope and application of the new insertion site in vaccine preparation. It is found that a foot-and-mouth disease virus antigen epitope is inserted between 62nd-63rd amino acids of an Encapsulin protein fragment after amino acid sequence modification, and / or the 62nd-63rd amino acids are replaced with the foot-and-mouth disease virus antigen epitope, efficient and soluble expression of a target antigen in escherichia coli can be achieved, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized anti-foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a foot-and-mouth disease vaccine.

The present invention describes chimeric proteins having albumin or truncated albumin covalently linked to one or more oxygen-binding proteins or protein fragments or variants, their preparation and use

Methods comprise exposing a culture of human pluripotent stem cells adherent on a first substrate comprising a first laminin to a differentiation medium for a first time period of 15 days to 50 days to obtain a first population of adherent cells comprising RPE cells and / or progenitors thereof; at the end of the first time period, dissociating the first population from the first substrate; replating the dissociated first population of cells on a second substrate comprising a second laminin; and culturing the replated first population of cells on the second substrate for a second time period to obtain an expanded and matured second population of cells comprising the RPE cells. The first and second laminins are independently selected from LN-521, LN-511, LN-111 and LN-121, and are an intact protein or protein fragment. Also included are RPE cells and materials and compositions utilizing such RPE cells for various treatments.

This disclosure relates to modified HIV envelope proteins or envelope protein fragments, or trimeric complexes thereof which have uses in vaccination methods or therapeutic strategies. In certain embodiments, this disclosure relates to modified HIV envelope proteins or envelope protein fragments, or trimeric complexes thereof, comprising an arginine (R) at position 166, glutamine (Q) at position 170, and an amino acid histidine (H) at position 173. In certain embodiments, this disclosure relates to nucleic acids and recombinant vectors encoding said proteins.

The invention provides for a screening assay-using a selective proteolysis of recombinant full-length PIKfyve at an endogenous caspase 3 cleavage site to liberate the 34 kDa C -terminal kinase domain. Despite instability of the kinase domain to isolation, the liberated kinase domain is stable in the presence of the N-terminal PIKfyve protein fragment and can thus be treated with compounds of interest and analyzed by mass spectrometry, such as RapidFire-MS, with each injection taking under one minute. The assay was established to triage small molecules for covalent modification of PIKfyve. The assay was also established using cysteine-mutant proteins, where the reactive cysteine was replaced with an inert amino acid which when run through the same experimental protocol, was used to confirm adduct formation at the target cysteine.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The application discloses a PSAP-3 protein fragment and application thereof in human echinococcosis. The polypeptide comprises an amino acid sequence as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4. The application further discloses a recombinant protein or a mutation thereof, wherein the recombinant protein comprises an amino acid sequence as shown in SEQ ID NO:5, and the amino acid sequence of the mutation has at least 80% identity with the amino acid sequence of the recombinant protein. The immunoreaction rate of the PSAP-3 recombinant protein of the application is 100%, the echinococcosis can be effectively detected, the positive detection rate is 96%, the negative detection rate is 90%, and the positive patient that cannot be detected by Egr can be detected.

The invention provides a kidney transplantation rejection reaction serum polypeptide detection device and method, and the method comprises the steps: obtaining a kidney transplantation serum sample, and extracting a polypeptide characteristic signal group of the serum sample from a polypeptide mass spectrum of the serum sample in a preset mass-to-charge ratio range; the polypeptide characteristic signal group comprises three characteristic polypeptide peak signals corresponding to different protein fragments, and further determining the mass-to-charge ratio of each protein fragment and the relative intensity value of each characteristic polypeptide peak in the polypeptide characteristic signal group; carrying out fusion judgment on the rejection risk of the serum sample according to the mass-to-charge ratio of each protein fragment and the relative intensity value of each characteristic polypeptide peak in the polypeptide characteristic signal group to obtain a risk index representing the rejection state in the serum sample; and comparing the risk index with a rejection risk threshold value of the serum sample so as to make multi-level judgment on the rejection risk level to which the serum sample belongs. Based on the scheme, rejection reaction monitoring based on kidney transplantation serum polypeptide fingerprints can be realized.

The invention provides a recombinant glycoprotein trimer vaccine for preventing SFTS and application thereof, the vaccine comprises a recombinant Gn or Gc glycoprotein trimer, and the recombinant Gn or Gc glycoprotein trimer is composed of a Gn or Gc protein fragment and a corresponding trimer motif; the amino acid sequences of the Gn and Gc protein fragments are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2, and the motif of the trimer is T4, DMPK, MTQ, MTI, hCorla, Langerin, T3XV, MATN1 or CAT. Results show that the neutralizing antibody level induced by the Gn or Gc trimer is superior to that of a corresponding monomer or dimer, and the Gn or Gc trimer has higher cross-neutralization activity. Meanwhile, monomers and trimers of Gn or Gc can induce high-level Th1 and Th2 cytokines and antibody-dependent cytotoxic effect (ADCC) response. According to the invention, a dominant antigen structure which can more effectively stimulate the generation of the neutralizing antibody in the SFTSV is defined, and a new target spot and a new strategy are provided for enhancing immunogenicity in the research and development of the SFTSV vaccine.

Provided herein include new antibodies reactive for canine CD3, which are shown to substantially increase activation of canine T cells; new multi-specific immune cell engager molecules based on the canine CD3 antibodies, which are shown to effectively bind canine cancer antigens and recruit T cells for killing of the cancer cells; as well as new recombinant proteins derived from canine cartilage protein fragments and hydrogels thereof. Uses of these compositions are also provided, which include therapeutic uses of antibodies and multi-specific immune cell engager molecules for treatment of cancers or other diseases in dogs, as well as uses of hydrogels for local immunotherapy delivery for reduction of post-surgical recurrence risk, reduction of cancer at surgically inoperable sites, provision of palliation, and / or substitution for surgery.

The present invention is related to the field of targeted drug delivery. In particular, the particles and compositions described herein are used to deliver drugs to treat the diseases and conditions of interest. These particles and compositions include, but are not limited to, the lipopeptide complexes that mimic human high-density lipoproteins but contain apolipoprotein fragments or combination thereof.

A composition, preferably a cosmetic composition, comprising - a rapeseed protein hydrolysate comprising protein fragments, wherein at least 50% (w / w) of the protein fragments has a molecular weight of less than 3.5 kDa; and - optionally a cosmetically acceptable further ingredient.

A reporter for an intramolecular protein-fragment complementation assay, wherein the reporter is a fused protein comprising a first fragment, a second fragment and an E3 ligase sequence section, wherein the first fragment and the second fragment are derived from different sections of the same split protein, preferably luciferase split protein, and fragments of the split protein are configured for providing a signal indicating an assembly of the first fragment and the second fragment, wherein the E3 ligase sequence section intervenes between the first fragment and the second fragment, wherein E3 ligase sequence section is derived from an E3 ligase reference sequence, as well as a polynucleotide, a cell and methods for conducting such an assay.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The application provides a recombinant collagen XVII fragment, and the protein fragment sequence is shown as SEQ ID No. 1. The recombinant collagen XVII fragment is designed based on a natural collagen sequence, has a triple helix structure, and has good biological activity, and can effectively play a function, and has a good promoting effect on cell migration, cell proliferation and cell adhesion. The method for preparing the recombinant collagen XVII fragment has simplified process steps, improves the expression efficiency of the recombinant protein, and reduces the production cost. The recombinant collagen XVII fragment has good mechanical properties and biological activity, and can be used for preparing a therapeutic drug and a biological material.

This document discloses performance garments infused with silk and methods for their preparation. In some embodiments, the performance silk garments comprise textiles, fabrics, consumer products, leather, and other materials coated with an aqueous solution of pure silk fibroin-based protein fragments. In some embodiments, the coated garment products, textiles, interior materials, and other materials exhibit surprisingly improved moisture management properties, resistance to microbial growth, enhanced abrasion resistance, and fire resistance.

The present application relates to a kind of fusion immunoglobulin and its application in culture T cell, belong to biological medicine technical field.The present application provides a kind of fusion immunoglobulin, the fusion immunoglobulin is the immunoglobulin of fusion IL-2 protein fragment, IL-21 protein fragment and IL-15 protein fragment.The fusion immunoglobulin constructed will IL-15, IL-21 and IL-2 be delivered together, effectively simulate in-vivo environment, promote T cell proliferation, induced T cell has high killing, low exhaustion and strong memory and so on excellent phenotype, significantly prolong cytokine half-life.The fusion immunoglobulin of the present application is added in culture medium, and the fusion protein culture medium is prepared, avoids animal source serum component, batch consistency is excellent.The fusion immunoglobulin in culture medium can be accurately, synergistically and long-acting stimulation to T cell.

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by different foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum foot-and-mouth disease vaccine.

This invention relates to the field of enzyme catalysis technology, specifically to a deep-sea-derived protein fragment and its application as a penicillin cyclase. The protein is (a1) K141 1913, composed of the amino acid sequence shown in Sequence 1 of the sequence listing. The penicillin cyclase of this invention catalyzes the reaction of the substrate PenG to generate G-7-ADCA. Compared with existing chemical synthesis methods, the G-7-ADCA synthesis method provided by this invention has advantages such as being green, environmentally friendly, and low-cost, laying a solid foundation for the large-scale industrial production of G-7-ADCA.

The invention discloses a Griffithsin-IL18 fusion protein and a preparation method and application thereof.The Griffithsin-IL18 fusion protein comprises a Griffithsin protein fragment, an IL18 protein fragment and a flexible connecting peptide connecting the Griffithsin protein fragment and the IL18 protein fragment, the Griffithsin protein fragment is located at the N end of the fusion protein, and the IL18 protein fragment is located at the C end of the fusion protein. According to the present invention, the dual functions of virus infection blocking and immune activation are achieved, the Griffithsin fragment is specifically combined with host cell surface integrin to induce internalization and block virus endocytosis, and the IL-18 fragment activates NK cells so as to improve the overall antiviral efficiency and achieve the precise targeting intervention on the infected cells.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.